Startups
We have a nontoxic short duration breast cancer treatment. Our main drug is an intracellular cancer killing peptide eradicating 100% of ALL breast cancer cells in 96 hours in vitro and 91% of ALL breast cancer cells within 14 days in vivo. While our cancer targeting Cell Penetrating Peptide (CPP) delivers our cancer killing cargo with no healthy cell interaction. Our CPP can also be conjugated to increase efficacy by 4-6x and decrease toxicity by 6-20x of currently approved FDA chemotherapeutics
Overview
Location
United States, Massachusetts, Cambridge
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 19, 2018 | MassChallenge Names Top 2018 Startups in Boston and Rhode Island | September 19, 2018, BOSTON – MassChallenge, a global network of zero-equity startup accelerators, today announced the top startups from its 2018 Boston and Rhode Island programs, which together accelerated more than 150 startups across indu... |
| May 23, 2018 | Announcing the 2018 MassChallenge Boston Cohort | We’re thrilled to introduce this year’s MassChallenge Boston cohort, which was selected from more than 1,600 applications from around the world, including 11 countries and 16 U.S. states. Representing the top 8% of all applicants, these 128... |
Reviews 0
FAQ about MicroQuin
What has the press written about MicroQuin?
Parsers VC has collected 3 articles mentioning MicroQuin, among them “MassChallenge Names Top 2018 Startups in Boston and Rhode Island” (Sep 19, 2018) and “Announcing the 2018 MassChallenge Boston Cohort” (May 23, 2018).
Is MicroQuin still active?
Yes, MicroQuin is active; its latest activity on Parsers VC dates from Oct 17, 2018.